amifostine anhydrous has been researched along with Lymph Node Metastasis in 8 studies
Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Small, W | 4 |
| Winter, K | 1 |
| Levenback, C | 1 |
| Iyer, R | 1 |
| Hymes, SR | 1 |
| Jhingran, A | 1 |
| Gaffney, D | 1 |
| Erickson, B | 1 |
| Greven, K | 1 |
| Astudillo, L | 1 |
| Maachi, B | 1 |
| Benyoucef, A | 1 |
| Game, X | 1 |
| Rives, M | 1 |
| Bachaud, JM | 1 |
| De Los Santos, JF | 1 |
| Mazeron, JJ | 1 |
| Buzaid, AC | 1 |
| Murren, J | 1 |
| Durivage, HJ | 1 |
| Glover, D | 1 |
| Glick, JH | 1 |
| Weiler, C | 1 |
| Fox, K | 1 |
| Guerry, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Two Part Phase I/II Study Of Extended Field External Irradiation And Intracavitary Brachytherapy Combined With Chemotherapy And Amifostine In Carcinoma Of The Cervix With Positive Para-Aortic Or High Common Iliac Lymph Nodes[NCT00012012] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The second part of this study (second arm) was designed to detect a 40% relative reduction (absolute from 77% to 46%) in the acute grade 3/4 toxicity (excluding grade 3 leukopenia) rate, with the addition of amifostine. A one-sided alpha of 0.05 and 80% power required 16 evaluable patients to detect the hypothesized difference. If ≤ 8 had the toxicity, it would be concluded that adding amifostine decreased this toxicity rate by at least 40%. (NCT00012012)
Timeframe: From start of treatment to 90 days
| Intervention | participants (Number) |
|---|---|
| Radiation Therapy Plus Cisplatin and Amifostine | 13 |
To determine the feasibility and tolerance of extended-field external radiotherapy to the pelvis and para-aortic region and intracavitary irradiation combined with weekly cisplatin using the rate of acute grade 3/4 toxicity rate (excluding grade 3 leukopenia). The first part of this study was designed to determine the acute grade 3/4 toxicity rate (excluding grade 3 leukopenia), to have a starting point for the second part (second arm) of the study. (NCT00012012)
Timeframe: From start of treatment to 90 days
| Intervention | percentage of participants (Number) |
|---|---|
| Radiation Therapy Plus Cisplatin | 81 |
2 reviews available for amifostine anhydrous and Lymph Node Metastasis
| Article | Year |
|---|---|
The role of amifostine in the treatment of carcinoma of the uterine cervix: an update of RTOG-0116 and review of future directions.
Topics: Amifostine; Clinical Trials as Topic; Combined Modality Therapy; Cryoprotective Agents; Female; Huma | 2004 |
The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review.
Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fe | 2002 |
3 trials available for amifostine anhydrous and Lymph Node Metastasis
| Article | Year |
|---|---|
Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Brachytherapy; Carcinoma; Cisplatin; Female; Humans; | 2011 |
Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial.
Topics: Amifostine; Antineoplastic Agents; Brachytherapy; Cisplatin; Combined Modality Therapy; Female; Huma | 2003 |
High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug | 1991 |
3 other studies available for amifostine anhydrous and Lymph Node Metastasis
| Article | Year |
|---|---|
Stevens-Johnson syndrome after amifostine during radiotherapy.
Topics: Amifostine; Carcinoma; Humans; Injections, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Rad | 2004 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; | 1987 |